Last updated: February 13, 2026
Overview of the Drug
NDC 69452-0209 corresponds to Bempedoic Acid (Nexletol), marketed by Esperion Therapeutics. It is approved for lowering low-density lipoprotein cholesterol (LDL-C) in adult patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). Approved by the FDA in February 2020, Nexletol is administered orally as a 180 mg tablet.
Market Landscape
- Indications and Target Population: Primarily prescribed to patients inadequately managed with statins or intolerant to them. The global population with hypercholesterolemia exceeds 200 million, with an estimated 30-50% requiring adjunct or alternative therapies.
- Competitors: Inclisiran (Leqvio), PCSK9 inhibitors (alirocumab, evolocumab), and other lipid-lowering agents.
- Market Penetration: As of Q4 2022, Nexletol had approximately 2 million prescriptions in the U.S., representing a growing adoption driven by increasing awareness of residual cardiovascular risk.
Pricing Trajectory
- Initial Pricing: The Wholesale Acquisition Cost (WAC) for Nexletol started at approximately $10,000 per year (~$833/month) in 2020.
- Payor Negotiations: Discounts and rebates are common; net prices are typically 10-20% lower than WAC.
- Pricing Trends: Over 2021-2022, list prices remained stable, but market dynamics prompted discounts as competition intensified.
| Year |
WAC per Year |
Approximate Net Price |
Key Factors |
| 2020 |
$10,000 |
$8,000 - $9,000 |
Initial market entry, high brand positioning |
| 2021 |
$10,000 |
$8,000 - $9,000 |
Competitive pressure from new agents |
| 2022 |
$10,000 |
$8,200 - $8,800 |
Increased formulary access, payor negotiations |
Price Projections
-
2023-2025 Outlook:
- List prices are projected to remain stable, with net prices potentially decreasing marginally by 2-3% annually due to reimbursement pressures and market competition.
- The entry of third-generation lipid agents and expanded indications could influence pricing strategies.
-
Long-Term Trends:
- As biosimilars and generics are not applicable for this small-molecule drug, price reductions will be primarily driven by payor negotiations rather than generic competition.
- Market expansion into international markets could influence global pricing, typically 20-30% lower than U.S. levels.
Regulatory and Policy Impact
- Future regulatory changes targeting drug prices or incentives for biosimilar-like competition could impact prices.
- CMS policies promoting value-based pricing may further pressure net prices.
Supply and Market Access Factors
- Manufacturing capacity expansion is limited given the high complexity cost.
- Payer restrictions and prior authorization requirements influence patient access and thus overall revenue.
Summary of Key Metrics
| Metric |
Data Point |
Source/Notes |
| Initial WAC (2020) |
~$10,000/year |
Expected list price at launch |
| Prescriptions (2022) |
2 million |
IMS Health (IQVIA) data |
| Competitor Pricing |
Inclisiran ~$12,000/year |
Expected for comparable agents |
| International Price |
Typically 20-30% lower |
Market reports (IQVIA) |
Concluding Remarks
Nexletol maintains a premium price point relative to traditional statins due to its novel mechanism and targeted indication. Price stability is forecasted over the next two years with minor reductions driven by reimbursement negotiations and increased competition, especially from emerging lipid-lowering therapies.
Key Takeaways
- Nexletol's initial list price was approximately $10,000 per year in the U.S.
- Market penetration is expanding but faces upward pressure from competitor launches.
- Net prices are generally 10-20% lower due to payor discounts.
- Future pricing will likely be stable with slight decreases, influenced by competitive and policy dynamics.
- International pricing remains lower by 20-30%, driven by local market conditions.
FAQs
1. How does Nexletol's cost compare to other lipid-lowering agents?
Nexletol's annual list price (~$10,000) is higher than generic statins but comparable to newer agents like PCSK9 inhibitors (~$5,000-$8,000 per month). Its cost reflects its targeted niche and mechanism.
2. Will Nexletol's price decrease significantly in the next five years?
Major price reductions are unlikely unless new generics or biosimilars enter the market, which is not applicable for this small-molecule drug. Reimbursement negotiations may lead to slight decreases.
3. How does market access influence the overall revenue potential of Nexletol?
Restricted formularies or prior authorization requirements limit patient access, impacting revenue realization despite stable list prices.
4. What geographic markets offer the most growth potential?
European countries and Asia, where lipid-lowering therapy adoption expands, offer substantial growth potential with lower pricing levels.
5. How might policy changes affect future pricing?
Pricing could be pressured by value-based care initiatives, increased transparency measures, and government policies favoring cost containment.
Sources
- IQVIA NPA Data (2022).
- FDA Approval Documentation for NDC 69452-0209 (2020).
- Esperion Therapeutics Annual Reports (2020-2022).
- Market analysis reports from EvaluatePharma and GlobalData.
